GlassScriptPhysician profile
Sonia A Talwar
NPI 1689655946
$13,265.38
in general payments reported to CMS, 2019-2025
57 companies · $1,627 in 2025
The $1,627 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $693 · 2020: $4,096 · 2021: $1,230 · 2022: $2,471 · 2023: $1,692 · 2024: $1,457 · 2025: $1,627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,340 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $300 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,339.60 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $300.00 |
| Education | $136.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $3,730.32 | 2020-2025 | Omnipod |
| Tandem Diabetes Care, INC. | $1,460.16 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Novo Nordisk INC | $1,082.68 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $839.29 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Amgen INC. | $663.31 | 2019-2025 | Evenity, Tepezza, Prolia |
| Lilly USA, LLC | $526.72 | 2020-2025 | Zepbound, Jardiance, Mounjaro |
| Xeris Pharmaceuticals, INC. | $426.01 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Amneal Pharmaceuticals LLC | $379.89 | 2019-2025 | Unithroid |
| Radius Health, INC. | $344.42 | 2020-2025 | Tymlos |
| Abbvie INC. | $258.79 | 2019-2025 | Ubrelvy, Synthroid |
| Corcept Therapeutics | $247.00 | 2022-2025 | Korlym |
| Ibsa Pharma INC. | $240.08 | 2022-2025 | Tirosint, Licart, Flector |
| Abbott Laboratories | $210.42 | 2020-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $182.71 | 2019-2022 | |
| Dexcom, INC. | $181.33 | 2022-2025 | Dexcom G6 Transmitter |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Talwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.